Our laboratories have recently developed a method of monitoring tumor progression in vivo using a bioluminescent reporter in intact animals. A potential immunotherapeutic intervention was evaluated in living animals and compared to a standard chemotherapy. Earlier work demonstrated that a population of human T cells expanded ex vivo, termed cytokine induced killer (CIK) cells, had potent anti-tumor activity against a variety of human lymphoma cell lines both in culture and when engrafted into severe combined immunodeficiency (SCID) mice. These cells were derived from T cell precursors and express the NK cell marker CD56. Human CIK cells from in vitro activation of peripheral blood mononuclear cells, were used against a human cell target in this study in order to establish an in vivo model system to monitor immune therapies and tumor growth. A stable HeLa cell line that constitutively expressed a modified firefly luciferase gene was used as the target cells. These bioluminescent target cells were injected intraperitoneally (IP) into 3 groups of 5 irradiated SCID mice and treated with either the CD3+CD56+ cells, cyclophosphamide or PBS. The luciferase substrate (luciferin) was introduced IP 20 min. prior to imaging the mice with an intensified charge coupled device (ICCD) camera. Mice were imaged weekly for 4 weeks and tumor growth measured using bioluminescence as a reporter. The control animals showed graded increases in light intensity over time. Treatment of the mice with the CD3+CD56+ cells (CIK) or cyclophosphamide resulted in reduction of light intensity compared to control animals. This noninvasive method allowed convenient, real time analyses of tumor growth and regression in living animal models of human cancer.
Read full abstract